(Gatralimab)Biosimilar Reference Antibody-GS40296 新品

货号：GS40296

Gatralimab is a next-generation anti-CD52 monoclonal antibody (mAb) that was investigated for the treatment of progressive multiple sclerosis (MS). It belongs to the class of therapies aimed at immune cell depletion to modulate the pathogenic immune response in MS. Gatralimab functions by binding to the CD52 antigen on the surface of a broad range of immune cells, including T cells, B cells, and monocytes. Upon binding, it leads to the depletion of these target cells, primarily through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).